Stéphane Dalle

25.5k total citations · 1 hit paper
325 papers, 9.1k citations indexed

About

Stéphane Dalle is a scholar working on Oncology, Molecular Biology and Dermatology. According to data from OpenAlex, Stéphane Dalle has authored 325 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 174 papers in Oncology, 102 papers in Molecular Biology and 85 papers in Dermatology. Recurrent topics in Stéphane Dalle's work include Cancer Immunotherapy and Biomarkers (81 papers), Cutaneous Melanoma Detection and Management (75 papers) and Cutaneous lymphoproliferative disorders research (70 papers). Stéphane Dalle is often cited by papers focused on Cancer Immunotherapy and Biomarkers (81 papers), Cutaneous Melanoma Detection and Management (75 papers) and Cutaneous lymphoproliferative disorders research (70 papers). Stéphane Dalle collaborates with scholars based in France, United States and Spain. Stéphane Dalle's co-authors include L. Thomas, B. Balme, D. Bataille, Alice Phan, S. Ronger-Savlé, Safia Costes, S. Debarbieux, Jerrold M. Olefsky, Christophe Broca and Gyslaine Bertrand and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Stéphane Dalle

301 papers receiving 9.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

2019 703 citations Georgina V. Long, Reinhard Dummer et al. profile →

Peers

Countries citing papers authored by Stéphane Dalle

Since Specialization

Citations

This map shows the geographic impact of Stéphane Dalle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Dalle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Dalle more than expected).

Fields of papers citing papers by Stéphane Dalle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Dalle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Dalle. The network helps show where Stéphane Dalle may publish in the future.

Co-authorship network of co-authors of Stéphane Dalle

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Dalle. A scholar is included among the top collaborators of Stéphane Dalle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Dalle. Stéphane Dalle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma 2025 ·Annals of Oncology ·Paolo A. Ascierto, Michele Del Vecchio, Barbara Merelli, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, (unknown), Jacopo Pigozzo, Iván Márquez‐Rodas, (unknown), Anna Maria Di Giacomo, Mark R. Middleton, (unknown), Luis de la Cruz‐Merino, (unknown), (unknown), Margarita Askelson, James Larkin	0
2	Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update 2025 ·European Journal of Cancer ·Evan J. Lipson, F. Stephen Hodi, Hussein Tawbi, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, (unknown), J. Menezes, Stéphane Dalle, Ana Arance, Caroline Gaudy‐Marqueste, Bingshu E. Chen, William T. Jackson, (unknown), Sonia Dolfi, Georgina V. Long	1
3	Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight‐adjusted dose, a multicenter observational study 2024 ·Cancer ·(unknown), Stéphane Dalle, Laurent Mortier, O. Dereure, (unknown), Caroline Dutriaux, M.‐T. Leccia, Délphine Legoupil, Henri Montaudié, Julie De Quatrebarbes, Caroline Gaudy‐Marqueste, E. Maubec, Philippe Saïag, Cécile Pagès, (unknown), F. Granel‐Brocard, Raphaël Porcher, (unknown), Célèste Lebbé, Emmanuelle Kempf	2
4	Cancer Cell Biomechanical Properties Accompany Tspan8-Dependent Cutaneous Melanoma Invasion 2024 ·Cancers ·(unknown), (unknown), (unknown), Muriel Cario, Simon Durand, (unknown), Manfred Schartl, Stéphane Dalle, Julie Caramel, (unknown), Ingrid Masse	2
5	When to stop immunotherapy for advanced melanoma: Emulation of target trials. 2024 ·Journal of Clinical Oncology ·(unknown), Laurent Mortier, Stéphane Dalle, O. Dereure, S. Dalac, Caroline Dutriaux, M.‐T. Leccia, E. Maubec, Jean‐Philippe Arnault, F. Brunet‐Possenti, Julie De Quatrebarbes, (unknown), Caroline Gaudy‐Marqueste, Cécile Pagès, Pierre‐Emmanuel Stoebner, Délphine Legoupil, Henri Montaudié, (unknown), Célèste Lebbé, Raphaël Porcher	0
6	Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study. 2024 ·Journal of Clinical Oncology ·Reinhard Dummer, Jean‐Jacques Grob, Caroline Robert, Ronnie Shapira‐Frommer, Célèste Lebbé, Paolo A. Ascierto, Stéphane Dalle, Omid Hamid, Nicolás Meyer, Muhammad Adnan Khattak, Andrew Hill, Jonathan Cohen, Giuseppe Curigliano, Anna Maria Di Giacomo, Michele Del Vecchio, Sekwon Jang, (unknown), Xuan Peng, Scott J. Diede, Georgina V. Long	2
7	Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients 2024 ·OncoImmunology ·Stéphane Dalle, Estelle Verronèse, (unknown), (unknown), Céline Rodriguez, Thibault Andrieu, (unknown), (unknown), (unknown), (unknown), Julie Caramel, Mona Amini‐Adlé, Nathalie Bendriss‐Vermare, Bertrand Dubois, Christophe Caux, Christine Ménétrier‐Caux	1
8	Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. 2023 ·Journal of Clinical Oncology ·Hussein A. Tawbi, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, (unknown), (unknown), (unknown), Sonia Dolfi, Georgina V. Long	7
9	1051P Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: Interim results from the ATLAS-IT-05 trial 2023 ·Annals of Oncology ·Stéphane Dalle, Thomas U. Marron, Caroline Robert, Badr Aljabri, Marta Nyakas, Karsten Bruins Slot, Vibeke Sundvold, Øystein Rekdal, Baldur Sveinbjørnsson, Graeme Currie	4
10	Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort 2023 ·JHEP Reports ·(unknown), (unknown), Fanny Lebossé, Xavier Quantin, C. Lesage, (unknown), (unknown), Stéphanie Faure, Georges‐Philippe Pageaux, Eric Assénat, Laurent Alric, (unknown), Dominique Larrey, (unknown), Benjamin Rivière, Janick Sèlves, Stéphane Dalle, A. Maria, T. Comont, Lucy Meunier	43
11	An in vivo avian model of human melanoma to perform rapid and robust preclinical studies 2023 ·EMBO Molecular Medicine ·(unknown), Stéphane Dalle, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Delphine Maucort‐Boulch, (unknown), Valérie Castellani, Julie Caramel, Céline Delloye‐Bourgeois	2
12	Adipocyte Extracellular Vesicles Decrease p16INK4A in Melanoma: An Additional Link between Obesity and Cancer 2022 ·Journal of Investigative Dermatology ·Ikrame Lazar, Emily Clement, (unknown), David Estève, Stéphanie Dauvillier, Mohamed Moutahir, Stéphane Dalle, Véronique Delmas, Nathalie Andrieu‐Abadie, Lionel Larue, Catherine Muller, Laurence Nieto	6
13	ZEB1 transcription factor promotes immune escape in melanoma 2022 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), (unknown), Laurie Tonon, Jonathan Lopez, (unknown), B. Balme, (unknown), Arnaud de la Fouchardière, Lionel Larue, Alain Puisieux, Yenkel Grinberg‐Bleyer, Nathalie Bendriss‐Vermare, Bertrand Dubois, Christophe Caux, Stéphane Dalle, Julie Caramel	55
14	Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) 2021 ·Cancers ·(unknown), Christine Cugnet‐Anceau, Stéphane Dalle, Karim Chikh, Souad Assaad, Emmanuel Disse, Gérald Raverot, Françoise Borson‐Chazot, (unknown)	23
15	Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up 2020 ·Journal of Clinical Medicine ·(unknown), J. Abeillon, Stéphane Dalle, Souad Assaad, Françoise Borson‐Chazot, Emmanuel Disse, Gérald Raverot, Christine Cugnet‐Anceau	24
16	Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes 2019 ·Diabetes Care ·(unknown), Christine Cugnet‐Anceau, Corinne Vigouroux, (unknown), Stéphane Dalle, (unknown), Lucien Marchand, Olivier Lascols, (unknown), Charles Thivolet, Martine Laville, Emmanuel Disse	41
17	Adipocyte Exosomes Promote Melanoma Aggressiveness through Fatty Acid Oxidation: A Novel Mechanism Linking Obesity and Cancer 2016 ·Cancer Research ·Ikrame Lazar, Emily Clement, Stéphanie Dauvillier, Delphine Milhas, Manuelle Ducoux‐Petit, Sophie Le Gonidec, Cédric Moro, Vanessa Soldan, Stéphane Dalle, Stéphanie Balor, Muriel Golzio, Odile Burlet‐Schiltz, Philippe Valet, Catherine Muller, Laurence Nieto	281
18	Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101 2011 ·Molecular Cancer Therapeutics ·Stéphane Dalle, Lina Reslan, (unknown), (unknown), Frank Herting, Adriana Pleșa, Thomas Friess, Pablo Umaña, Christian Klein, Charles Dumontet	97
19	Extranuclear estrogen receptor-α stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis 2010 ·Proceedings of the National Academy of Sciences ·Winifred P.S. Wong, Joseph P. Tiano, (unknown), Sylvia C. Hewitt, Cédric Le May, Stéphane Dalle, John A. Katzenellenbogen, (unknown), Kenneth S. Korach, Franck Mauvais‐Jarvis	106
20	Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients 2010 ·Clinical Cancer Research ·Delphine Kérob, Raphaël Porcher, O Vérola, Stéphane Dalle, E. Maubec, F. Aubin, M. D’Incan, (unknown), S. Boulinguez, Isabelle Madelaine‐Chambrin, A. Mathieu-Boué, Jean-Marie Servant, É. de Kerviler, Anne Janin, Fabien Calvo, Florence Pédeutour, Célèste Lebbé	98

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact